VolitionRx Limited to Attend Multiple Conferences in September

5 Sep 2018 - Yahoo News
ISNES, Belgium , Sept. 5, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced that its Chief Executive Officer, Cameron Reynolds and/or its Executive Vice President of Investor ...
usx:vnrx

---

VNRX: More Compelling Prostate Cancer Data, Opportunities Remain for Near-Term Data-Driven Value Inflection

29 Aug 2018 - Yahoo News
VolitionRx (VNRX) reported Q2 financial results and provided a business update. Despite the significant operational progress, including that related to their numerous (and growing number of) trials in various cancers, operating spend through the first six months of 2018 was up just $2.4M (+35%) from ...
usx:vnrx

---

Volitionrx Limited to Host Earnings Call

14 Aug 2018 - Yahoo News
NEW YORK, NY / ACCESSWIRE / August 14, 2018 / Volitionrx Limited (NYSE MKT: VNRX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 8:30 AM Eastern Time. ...
usx:vnrx

---

VolitionRX: 2Q Earnings Snapshot

13 Aug 2018 - Yahoo News
The Singapore-based company said it had a loss of 15 cents per share. In the final minutes of trading on Monday, the company's shares hit $1.91. A year ago, they were trading at $2.92. _____ This story ...
usx:vnrx

---

VolitionRx Limited Announces Second Quarter 2018 Financial Results and Business Update

13 Aug 2018 - Yahoo News
ISNES, Belgium, Aug. 13, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the quarter ended June 30, 2018. Volition management will host a conference call to discuss these results and provide a further business update ...
usx:vnrx

---

Preliminary Data from Study Demonstrates 94% Accuracy in Detecting Aggressive Prostate Cancer

13 Aug 2018 - Yahoo News
ISNES, Belgium, Aug. 13, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced preliminary data from a prospective, multi-centered Proof of Concept Study of 84 men into the utility of Volition's Nu.Q™ assays to diagnose men with high-grade prostate cancer. At 88% ...
usx:vnrx

---

VolitionRx completes blood sample collection as part of joint University of Oxford endometriosis study - Proactive Investors USA & Canada

9 Aug 2018 - Proactive Investors USA & Canada

usx:vnrx

---

VolitionRx Limited Announces Completion of Sample Collection in Endometriosis Study

9 Aug 2018 - Yahoo News
ISNES, Belgium, Aug. 9, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that the 3-year sample collection has been completed in the prospective study undertaken in collaboration with the University of Oxford, England to assess Volition's proprietary Nu.Q™ platform ...
usx:vnrx

---

VolitionRx Announces $9 Million Private Placement - PR Newswire

8 Aug 2018 - PR Newswire

usx:vnrx

---

VolitionRx Announces $9 Million Private Placement - Markets Insider

8 Aug 2018 - Markets Insider

usx:vnrx

---